<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00594516</url>
  </required_header>
  <id_info>
    <org_study_id>CR014242</org_study_id>
    <secondary_id>R331333PAI3019</secondary_id>
    <nct_id>NCT00594516</nct_id>
  </id_info>
  <brief_title>Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain</brief_title>
  <official_title>A Randomized, Double-Blind, 2-Period, Crossover Study to Establish the Dose Equivalence and Direct Conversion Between Immediate Release (IR) and Extended-Release (ER) CG5503 in Subjects With Moderate-to-Severe, Chronic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gr√ºnenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <brief_summary>
    <textblock>
      The objective of this study is to test the idea that the immediate-release (IR) form of
      tapentadol (CG5503) can be directly converted into an approximately equivalent total daily
      dose (TDD) of the extended-release (ER) form, and vice-versa, with equivalent safety and
      efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will establish the dose equivalence and the safety and effectiveness of the
      Immediate Release (IR) and Extended Release (ER) forms of tapentadol (CG5503) to support the
      conversion from IR to ER, and ER to IR use. Dose equivalence will be examined in patients
      diagnosed with moderate-to-severe, chronic Low Back Pain (LBP) requiring drug treatment for
      at least 3 months, and who are dissatisfied with current therapy. The study consists of 5
      periods: a screening period during which patients are evaluated for study eligibility; a
      21-day open-label period to find the best, stable dose of tapentadol (CG5503) IR for each
      patient individually; a 14-day double-blind period when patients are randomly chosen either
      to continue for 14 days on the stable IR dose from the open-label period or switch to the ER
      form; a second, 14-day period during which patients switch to whichever form of tapentadol
      (CG5503) they did not take during the first 14-day period (the total daily dose [TDD] remains
      approximately equivalent for the IR and ER forms throughout both double-blind periods); and a
      follow-up period. During the study, pain levels will be recorded and overall safety measures
      taken. The expectation (thought) is that approximately equivalent doses of both forms of
      tapentadol (CG5503) provide equivalent effectiveness and safety and that the two forms can be
      directly converted by dividing the total daily dose by the number of times the drug is taken
      each day. During the 21-day open-label period, 50, 75 or 100mg of the IR form is given orally
      every 4 or 6 hours, starting with 50mg every 6 hours. Then, the dose, the frequency of giving
      the drug, or both may be increased, to a maximum TDD of 500mg, or decreased in 50 mg
      increments, with minimum TDD of 200 mg, until the optimal stable dose for a patient is found.
      During the 2 double-blind periods, a TDD approximately equivalent to the stable open-label
      dose is given orally in IR (or ER) form or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Difference in the Mean Average Pain Intensity Score on an 11-point Numerical Rating Scale (NRS) During the Last 3 Days of Each Double-blind Treatment Period. (Difference Between Two DB Randomization Treatment Sequences)</measure>
    <time_frame>14 days for each cross-over period</time_frame>
    <description>For this twice daily pain assessment, the subjects were to indicate the level of average pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated &quot;no pain&quot; and a score of 10 indicated &quot;pain as bad as you can imagine&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Requiring Rescue Medication During the DB Tapentadol IR Treatment</measure>
    <time_frame>14 days for each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Requiring Rescue Medication During the DB Tapentadol ER Treatment</measure>
    <time_frame>14 days for each cross-over period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Dose (TDD) of Tapentadol IR During the Double-blind Treatment Period</measure>
    <time_frame>14-day for each DB treatment period</time_frame>
    <description>Average total daily dose (TDD) of tapentadol IR during the double blind treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Daily Dose (TDD) of Tapentadol ER During the DB Treatment Period.</measure>
    <time_frame>14 days for each treatment period</time_frame>
    <description>Average total daily dose (TDD) of tapentadol ER during the double-blind treatment period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tapentadol (CG5503) Immediate Release (IR) Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100 150 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second,tapentadol (CG5503) Immediate Release IR 21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tapentadol (CG5503) Extended Release (ER) During 2 double blind periods: Tapentadol ER 100 150 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tapentadol (CG5503) Immediate Release IR</intervention_name>
    <description>21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tapentadol (CG5503) Extended Release (ER)</intervention_name>
    <description>During 2 double blind periods: Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tapentadol (CG5503) Immediate Release (IR)</intervention_name>
    <description>Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Low Back Pain (LBP) of non-malignant origin present for at least 3 months
             immediately before study entry

          -  Taking drug treatment for pain for at least 3 months before screening and who are
             dissatisfied with current therapy

          -  Subjects receiving opioid treatment must have a total daily opioid dose &lt;= 160 mg/day
             of oral morphine equivalent

          -  For entry into open label period patients must have a baseline score &gt;=5 on an
             11-point NRS, calculated as the average pain intensity during the last 3 days of the
             washout period

          -  For entry into the double-blind period subjects must have remained on the same optimal
             stable dose and frequency of tapentadol (CG5503) IR administration during the last 3
             days of the open-label treatment period

        Exclusion Criteria:

          -  Presence of conditions other than Low Back Pain (LBP) that could make it hard to
             assess or self-evaluate pain

          -  Surgery in low back area within 3 months of screening or expected surgery in the low
             back area during the study

          -  Any scheduled surgery or painful procedure during the study, or any clinically
             significant disease that, in the opinion of the investigator, may affect efficacy or
             safety assessments

          -  History of malignancy within the past 2 years, with the exception of basal cell
             carcinoma that has been treated and is no longer present

          -  Women who are pregnant or breast-feeding

          -  Moderately or severely impaired liver function

          -  Severely impaired kidney function

          -  History of chronic hepatitis B or C, or HIV, or presence of active hepatitis B or C in
             past 3 months

          -  History of seizure disorder

          -  Alcohol or drug abuse

          -  Uncontrolled high blood pressure

          -  Clinically relevant history of hypersensitivity, allergy, or contraindications to
             acetaminophen or opioid analgesics (or ingredients)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <results_first_submitted>April 28, 2009</results_first_submitted>
  <results_first_submitted_qc>July 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 26, 2010</results_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Leader</name_title>
    <organization>Johnson &amp; Johnson Pharmaceutical Research and Development, L.L.C.</organization>
  </responsible_party>
  <keyword>Low Back Pain</keyword>
  <keyword>Dose Equivalence</keyword>
  <keyword>Tapentadol (CG5503)</keyword>
  <keyword>Tapentadol-IR</keyword>
  <keyword>Tapentadol-ER</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first site opened on 30 November 2007. The recruitment period for this outpatient, multicenter study occurred between 10 December 2007 and 01 May 2008.</recruitment_details>
      <pre_assignment_details>The study consisted of screening period (up to 21 days), washout period (from 3 to 7 days), open label (OL) treatment period (3 weeks), followed by a double blind (DB) active treatment period, with crossover design of 2 randomized sequences of tapentadol immediate release (IR) to tapentadol extended release (ER) and tapentadol ER to IR (4 weeks)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tapentadol</title>
          <description>Subjects treated in the Tapentadol(CG5503) Immediate Release (IR) Open-Label period</description>
        </group>
        <group group_id="P2">
          <title>Tapentadol IR to ER</title>
          <description>Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second intervention period of double-blind phase</description>
        </group>
        <group group_id="P3">
          <title>Tapentadol ER to IR</title>
          <description>Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second intervention period of double-blind phase</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open Label (OL): Tapentadol IR</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="116">one patient was enrolled but lost to follow up at the start of open label therefore was not included</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Medication Non Compliant</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>DB: Tapentadol IR to ER &amp; ER to IR</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Medication Non compliant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tapentadol</title>
          <description>Subjects treated in the Tapentadol(CG5503) Immediate Release (IR) Open-Label period</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.6" spread="15.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race/ethnicity</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Difference in the Mean Average Pain Intensity Score on an 11-point Numerical Rating Scale (NRS) During the Last 3 Days of Each Double-blind Treatment Period. (Difference Between Two DB Randomization Treatment Sequences)</title>
        <description>For this twice daily pain assessment, the subjects were to indicate the level of average pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated &quot;no pain&quot; and a score of 10 indicated &quot;pain as bad as you can imagine&quot;.</description>
        <time_frame>14 days for each cross-over period</time_frame>
        <population>Per-protocol set defined as the number of randomized subjects who took at least one dose of study drug during the DB treatment period, and who met additional criteria which were identified prior to unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol</title>
            <description>Subjects treated in the Tapentadol Immediate Release (IR) Open-Label period (followed by randomization to double-blind crossover maintenance period in which all subjects receive both IR and ER formulations)</description>
          </group>
        </group_list>
        <measure>
          <title>The Difference in the Mean Average Pain Intensity Score on an 11-point Numerical Rating Scale (NRS) During the Last 3 Days of Each Double-blind Treatment Period. (Difference Between Two DB Randomization Treatment Sequences)</title>
          <description>For this twice daily pain assessment, the subjects were to indicate the level of average pain experienced over the previous 12 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated &quot;no pain&quot; and a score of 10 indicated &quot;pain as bad as you can imagine&quot;.</description>
          <population>Per-protocol set defined as the number of randomized subjects who took at least one dose of study drug during the DB treatment period, and who met additional criteria which were identified prior to unblinding.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.09" upper_limit="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tapentadol IR to ER analysis of variance model with factors for treatment, double blind cross-over period and subject.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin of (-2, 2). A prespecified equivalence margin of (-2,2) was used for equivalence analysis.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Requiring Rescue Medication During the DB Tapentadol IR Treatment</title>
        <time_frame>14 days for each cross-over period</time_frame>
        <population>DB safety set defined as randomized subjects who took at least one dose of study drug during the DB treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol</title>
            <description>Subjects treated in the Tapentadol Immediate Release (IR) Open-Label period (followed by randomization to double-blind crossover maintenance period in which all subjects receive both IR and ER formulations)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Requiring Rescue Medication During the DB Tapentadol IR Treatment</title>
          <population>DB safety set defined as randomized subjects who took at least one dose of study drug during the DB treatment period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Requiring Rescue Medication During the DB Tapentadol ER Treatment</title>
        <time_frame>14 days for each cross-over period</time_frame>
        <population>DB safety set defined as randomized subjects who took at least one dose of study drug during the DB treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol</title>
            <description>Subjects treated in the Tapentadol Immediate Release (IR) Open-Label period (followed by randomization to double-blind crossover maintenance period in which all subjects receive both IR and ER formulations)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Requiring Rescue Medication During the DB Tapentadol ER Treatment</title>
          <population>DB safety set defined as randomized subjects who took at least one dose of study drug during the DB treatment period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Dose (TDD) of Tapentadol IR During the Double-blind Treatment Period</title>
        <description>Average total daily dose (TDD) of tapentadol IR during the double blind treatment period</description>
        <time_frame>14-day for each DB treatment period</time_frame>
        <population>DB safety set defined as randomized subjects who took at least one dose of study drug during the DB treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol</title>
            <description>Subjects treated in the Tapentadol Immediate Release (IR) Open-Label period (followed by randomization to double-blind crossover maintenance period in which all subjects receive both IR and ER formulations)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Dose (TDD) of Tapentadol IR During the Double-blind Treatment Period</title>
          <description>Average total daily dose (TDD) of tapentadol IR during the double blind treatment period</description>
          <population>DB safety set defined as randomized subjects who took at least one dose of study drug during the DB treatment period.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331.0" spread="116.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Daily Dose (TDD) of Tapentadol ER During the DB Treatment Period.</title>
        <description>Average total daily dose (TDD) of tapentadol ER during the double-blind treatment period.</description>
        <time_frame>14 days for each treatment period</time_frame>
        <population>DB safety set defined as randomized subjects who took at least one dose of study drug during the DB treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol</title>
            <description>Subjects treated in the Tapentadol Immediate Release (IR) Open-Label period (followed by randomization to double-blind crossover maintenance period in which all subjects receive both IR and ER formulations)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Dose (TDD) of Tapentadol ER During the DB Treatment Period.</title>
          <description>Average total daily dose (TDD) of tapentadol ER during the double-blind treatment period.</description>
          <population>DB safety set defined as randomized subjects who took at least one dose of study drug during the DB treatment period.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330.4" spread="123.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events were reported from the time a signed and dated informed consent was obtained throughout the follow-up phase of the study (up to 63 days post dose). Serious adverse events were collected for 30 days after the last dose of study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tapentadol</title>
          <description>Subjects treated in the Tapentadol Immediate Release (IR) open-label and the double-blind crossover period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mila Etropolski, MD Clinical Leader</name_or_title>
      <organization>Johnson &amp; Johnson Pharmaceutical Research &amp; Development</organization>
      <phone>609-730-4537</phone>
      <email>metropol@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

